Antibiotic Treatment for H. influenzae Infections

Preferred First-Line Agents

The American Thoracic Society recommends co-amoxiclav 625 mg three times daily orally as the preferred first-line agent for non-pneumonic bronchial infections and non-severe pneumonia 1, 2, 5, 6
The American Thoracic Society recommends doxycycline 200 mg loading dose, then 100 mg once daily as an equally preferred alternative 1, 2, 5
For severe pneumonia requiring IV therapy, the American Thoracic Society recommends co-amoxiclav 1.2 g three times daily IV or ceftriaxone/cefotaxime 1-1.5 g three times daily IV 1, 2, 7

The Infectious Diseases Society of America recommends clarithromycin 500 mg twice daily as the preferred macrolide option when a macrolide is needed, due to better H. influenzae coverage 1, 2, 3, 4, 7
Erythromycin 500 mg four times daily is another macrolide option that ranks ahead of azithromycin 1, 2

Clarithromycin demonstrates superior in vitro and clinical activity against H. influenzae compared to azithromycin 1, 2, 3, 4, 7
18-42% of H. influenzae isolates produce β-lactamase, making β-lactamase-stable agents essential 6

The American Thoracic Society recommends identifying if H. influenzae is suspected pathogen and assessing penicillin allergy status to guide antibiotic selection 1, 4
If penicillin allergy is present, the American Thoracic Society recommends using doxycycline first, and if tetracycline is contraindicated or intolerant, using clarithromycin 500 mg BID instead of azithromycin 1, 2, 3, 4, 5

The American Thoracic Society recommends not using azithromycin as first-line empiric therapy when H. influenzae is a likely pathogen 1, 2, 3, 4
The Infectious Diseases Society of America recommends not assuming all macrolides are equivalent, as clarithromycin's superior H. influenzae activity is clinically significant 1, 2, 7